Press release
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious
About this update from Siga Technologies Inc.
[{"type":"text","content":"NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years. SIGA has been collaborating with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop the Post-exposure Prophylaxis (PEP) indication for oral TPOXX®, and this work has been supported by a development contract with a value of approximately $27 million (Contract number: MCDC1901-001-2019-400) as well as a Cooperative Research and Development Agreement. “We are pleased to announce this new contract, continuing our long-term partnership with the Department of Defense. Providing TPOXX® plays a critical role in protecting and supporting our military personnel against orthopoxvirus risks, such as smallpox. This underscores our commitment to ensuring the safety of our troops while also developing innovative treatments that benefit people worldwide as we advance the PEP indication,” said Diem Nguyen, Chief Executive Officer. Inclusive of this award, SIGA currently has approximately $154 million of outstanding oral and IV TPOXX® orders, of which more than 85% of this amount was generated within the past three months. Reference to the DOD, JPEO-CBRND, or other agency of the United States does not constitute or imply an endorsement or recommendation by the U.S. government or any agency thereof. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. O...